New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia

American Journal of Hematology

Volumn 86, Issue 7, 2011, Pages 619-621

  Cluzeau, Thomas ^a   De Matteis, Muriel ^a   Mounier, Nicolas ^a   Mannone, Lionel ^a   Gratecos, Nicole ^a   Ticchioni, Michel ^a   Thyss, Antoine ^b   Raynaud, Sophie ^a   Cassuto, Jill Patrice ^a   Sirvent, Anne ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BUSULFAN; CLOFARABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB; INOLIMOMAB; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OZOGAMICIN; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; HUMAN; INFECTION; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PUVA; REDUCED INTENSITY CONDITIONING; RELAPSE FREE SURVIVAL;

ADULT; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THIOTEPA; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 79959367740     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22029     Document Type: Letter

References (15)

1. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 1235-1248.
2. Dombret H, Gardin C. An old AML drug revisited. N Engl J Med 2009; 361: 1301-1303.
3. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656.
4. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223.
5. Mathe G, Amiel JL, Schwarzenberg L, et al. Successful allogenic bone marrow transplantation in man: Chimerism, induced specific tolerance and possible anti-leukemic effects. Blood 1965; 25: 179-196.
6. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
7. Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
8. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: Impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064-3070.
9. Thiede C, Bornhauser M, Oelschlagel U, et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001; 15: 293-302.
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
11. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
12. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
13. Richardson DS HC, Hill K, Newman J, Orchard KH. Improving outcome in high-risk acute myeloid leukaemia: A comparison of clofarabine and FlA-Ida pre-conditioning prior to full or reduced-intensity allogeneic stem cell transplant. EBMT Congress, Abstract 1328, 2010.
14. Buchholz S KJ, Dammann E, Beutel G, Stadler M, et al. Cytoreduction with clofarabine/Ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute leukaemia. EBMT Congress, Abstract 948, 2009.
15. de Lima M, Champlin RE, Thall PF, et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 2008; 22: 258-264.